These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35874853)

  • 1. The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.
    Zhao Y; Tian LG; Zhang LX; Ma T; Di L; Wang YB; Gu XS; Wang DD; Gao S; Wang H
    Pulm Circ; 2022 Jul; 12(3):e12034. PubMed ID: 35874853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
    Bouali Y; Galli E; Paven E; Laurin C; Arnaud H; Oger E; Donal E
    Adv Clin Exp Med; 2022 Feb; 31(2):109-119. PubMed ID: 34918885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study.
    Yang Y; Shen C; Lu J; Fu G; Xiong C
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):177-182. PubMed ID: 34711748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction.
    Masarone D; Errigo V; Melillo E; Valente F; Gravino R; Verrengia M; Ammendola E; Vastarella R; Pacileo G
    J Clin Med; 2020 Sep; 9(10):. PubMed ID: 33003523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Desai AS; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; McCague K; Abbas CA; Rocha R; Mitchell GF;
    JAMA; 2019 Sep; 322(11):1077-1084. PubMed ID: 31475296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
    El-Battrawy I; Demmer J; Abumayyaleh M; Crack C; Pilsinger C; Zhou X; Mügge A; Akin I; Aweimer A
    ESC Heart Fail; 2023 Apr; 10(2):943-954. PubMed ID: 36479630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies.
    Zhang J; Du L; Qin X; Guo X
    J Am Heart Assoc; 2022 May; 11(9):e024449. PubMed ID: 35470677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
    Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
    Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.
    Abumayyaleh M; Demmer J; Krack C; Pilsinger C; El-Battrawy I; Behnes M; Aweimer A; Mügge A; Lang S; Akin I
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):535-544. PubMed ID: 35353351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    De Vecchis R; Paccone A; Di Maio M
    Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry.
    Correale M; Mallardi A; Mazzeo P; Tricarico L; Diella C; Romano V; Ferraretti A; Leopizzi A; Merolla G; Di Biase M; Brunetti ND
    Int J Cardiol Heart Vasc; 2020 Apr; 27():100486. PubMed ID: 32140553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study.
    Halle M; Schöbel C; Winzer EB; Bernhardt P; Mueller S; Sieder C; Lecker LSM
    Eur J Heart Fail; 2021 Dec; 23(12):2073-2082. PubMed ID: 34591356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure.
    Correale M; Mazzeo P; Magnesa M; Fortunato M; Tricarico L; Leopizzi A; Mallardi A; Mennella R; Tucci S; Brunetti ND
    Clin Physiol Funct Imaging; 2021 Nov; 41(6):505-513. PubMed ID: 34510702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
    Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
    Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.